Thinking of starting COAGADEX? Talk with your doctor to see if COAGADEX is right for you.
If your doctor prescribes COAGADEX, check below for ways we can help to make it easier for you to begin.
Copay and Insurance Support
COAGADEX Copay Support Program
If you have a prescription for COAGADEX and are having a hard time paying for it, BPL may be able to help.
- Our COAGADEX Copay Support Program can help cover out-of-pocket expenses for your COAGADEX prescription.
- Some restrictions apply. To see if you qualify, register here.
Insurance coverage for COAGADEX
Register here if you have any questions about:
- Insurance coverage
- Prior authorizations and appeals (sometimes needed to approve coverage of COAGADEX)
Links for more information
Visit these sites for more information about factor X deficiency, including local and national events in the bleeding disorder community.
BPL works with the following pharmacies to make COAGADEX available for you.
Diplomat Pharmacy, Inc.
Hemophilia treatment centers
Many patients with bleeding disorders seek treatment at a Hemophilia Treatment Center (HTC). More than 140 HTCs are found across the US. They provide high-quality care for people with all types of bleeding disorders. Talk with your doctor about HTCs.
Indications and Usage for COAGADEX
COAGADEX, a plasma-derived blood coagulation factor X concentrate, is indicated in adults and children with hereditary factor X deficiency for:
- Routine prophylaxis to reduce the frequency of bleeding episodes
- On-demand treatment and control of bleeding episodes
- Perioperative management of bleeding in patients with mild and moderate hereditary factor X deficiency
Limitation of Use
Perioperative management of bleeding in major surgery in patients with severe hereditary factor X deficiency has not been studied.
Contraindication for COAGADEX
COAGADEX is contraindicated in patients with known hypersensitivity to any of the components of the product.
Important Safety Information for COAGADEX
Allergic type hypersensitivity reactions, including anaphylaxis, are possible with COAGADEX. If symptoms occur, patients should discontinue use of the product immediately, contact their physician, and administer appropriate treatment.
The formation of neutralizing antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency. Carefully monitor patients taking COAGADEX for the development of inhibitors by appropriate clinical observations and laboratory tests.
COAGADEX is made from human plasma and may contain infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD, have been associated with the use of COAGADEX.
In clinical studies, the most common adverse reactions (frequency ≥5% of subjects) with COAGADEX were infusion site erythema, infusion site pain, fatigue and back pain.